Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria

Abstract

This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against atypical upper respiratory pathogenic bacteria

What is claimed is:  
     
         1 . A method for modulating metabolism of atypical upper respiratory pathogenic bacteria comprising the step of contacting atypical upper respiratory pathogenic bacteria with an antibacterially effective amount of a composition comprising a gemifloxacin compound, or antibacterially effective derivatives thereof.  
     
     
         2 . The method of  claim 1  wherein said atypical upper respiratory pathogenic bacteria is selected from the group consisting of: 
 a member of the genus Legionella, a member of the genus, Pseudomonas,  Pseudomonas aeruginosa  strain, a  L. pneumophila  strain, a  L. Pneumophila  serogroup 1, a  L. Pneumophila  serogroup 2, a  L. pneumophila  serogroup 3, a  L. pneumophila  serogroup 4, a  L. Pneumophila  serogroup 5, a  L. pneumophila  serogroup 6, a  L. pneumophila  serogroup 7, a  L. pneumophila  serogroup 8, a  L. dumoffii  strain, a  L. longbeacheae  strain, a  L. micdadei  strain, a  L. oakridgensis  strain, a  L. feelei  strain, a  L. anisa  strain, a  L. sainthelensi  strain, a  L. bozemanii  strain, a  L. gormanii  strain, a  L. wadsworthii  strain, a  L. jordanis;  strain and a  L. gormanii  strain.  
 
     
     
         3 . A method of treating or preventing a bacterial infection by atypical upper respiratory pathogenic bacteria comprising the step of administering an antibacterially effective amount of a composition comprising a gemifloxacin compound to a mammal suspected of having or being at risk of having an infection with atypical upper respiratory pathogenic bacteria.  
     
     
         4 . The method of  claim 3  wherein said atypical upper respiratory pathogenic bacteria is selected from the group consisting of: a member of the genus Legionella, a member of the genus, Pseudomonas,  Pseudomonas aeruginosa  strain, a  L. pneumophila  strain, a  L. pneumophila  serogroup 1, a  L. pneumophila  serogroup 2, a  L. pneumophila  serogroup 3, a  L. pneumophila  serogroup 4, a  L. pneumophila  serogroup 5, a  L. pneumophila  serogroup 6, a  L. pneumophila  serogroup 7, a  L. pneumophila  serogroup 8, a  L. dumoffii  strain, a  L. longbeacheae  strain, a  L. micdadei  strain, a  L. oakridgensis  strain, a  L. feelei  strain, a  L. anisa  strain, a  L. sainthelensi  strain, a  L. bozemanii  strain, a  L. gormanii  strain, a  L. wadsworthii  strain, a  L. jordanis;  strain and a  L. gormanii  strain.  
     
     
         5 . The method of  claim 1  wherein said modulating metabolism is inhibiting growth of said bacteria.  
     
     
         6 . The method of  claim 1  wherein said modulating metabolism is killing said bacteria.  
     
     
         7 . The method of  claim 1  wherein said contacting said bacteria comprises the further step of introducing said composition into a mammal.  
     
     
         8 . The method of  claim 3  wherein said mammal is a human.  
     
     
         9 . The method of  claim 7  wherein said mammal is a human.  
     
     
         10 . The method of  claim 1  wherein said bacteria is selected from the group consisting of: a member of the genus Legionella, a member of the genus, Pseudomonas,  Pseudomonas aeruginosa  strain, a  L. pneumophila  strain, a  L. pneumophila  serogroup 1, a  L. pneumophila  serogroup 2, a  L. pneumophila  serogroup 3, a  L. pneumophila  serogroup 4, a  L. pneumophila  serogroup 5, a  L. pneumophila  serogroup 6, a  L. Pneumophila  serogroup 7, a  L. pneumophila  serogroup 8, a  L. dumoffii  strain, a  L. longbeacheae  strain, a  L. micdadei  strain, a  L. oakridgensis  strain, a  L. feelei  strain, a L. anisa strain, a  L. sainthelensi  strain, a  L. bozemanii  strain, a  L. gormanii  strain, a  L. wadsworthii  strain, a  L. jordanis;  strain and a  L. gormanii  strain.  
     
     
         11 . The method of  claim 1  wherein said bacteria is selected from the group consisting of: a member of the genus Legionella, a member of the genus, Pseudomonas,  Pseudomonas aeruginosa  strain, a  L. pneumophila  strain, a  L. pneumophila  serogroup 1, a  L. pneumophila  serogroup 2, a  L. pneumophila  serogroup 3, a  L. pneumophila  serogroup 4, a  L. pneumophila  serogroup 5, a  L. pneumophila  serogroup 6, a  L. pneumophila  serogroup 7, a  L. pneumophila  serogroup 8, a  L dumoffii  strain, a  L. longbeacheae  strain, a  L. micdadei  strain, a  L. oakridgensis  strain, a  L. feelei  strain, a L. anisa strain, a  L. sainthelensi  strain, a  L. bozemanii  strain, a  L. gormanii  strain, a  L. wadsworthii  strain, a  L. jordanis;  strain and a  L. gormanii  strain.  
     
     
         12 . A method for modulating metabolism of atypical upper respiratory pathogenic bacteria comprising the step of contacting atypical upper respiratory pathogenic bacteria with an antibacterially effective amount of a composition comprising a compound selected from the group consisting of: gemifloxacin, ofloxacin, levofloxacin, trovafloxacin, azithromycin, moxifloxacin, ciprofloxacin, clarithromycin, rifampicin and erythromycin; 
 or an antibacterially effective derivative of any of these compounds.    
     
     
         13 . The method of  claim 12  wherein said bacteria is selected from the group consisting of: a member of the genus Legionella, a member of the genus, Pseudomonas,  Pseudomonas aeruginosa  strain, a  L. pneumophila  strain, a  L. pneumophila  serogroup 1, a  L. pneumophila  serogroup 2, a  L. pneumophila  serogroup 3, a  L. pneumophila  serogroup 4, a  L. pneumophila  serogroup 5, a  L. pneumophila  serogroup 6, a  L. pneumophila  serogroup 7, a  L. pneumophila  serogroup 8, a  L. dumoffii  strain, a  L. longbeacheae  strain, a  L. micdadei  strain, a  L. oakridgensis  strain, a  L. feelei  strain, a  L. anisa  strain, a  L. sainthelensi  strain, a  L. bozemanii  strain, a  L. gormanii  strain, a  L wadsworthii  strain, a  L. jordanis;  strain and a  L. gormanii  strain.  
     
     
         14 . The method of  claim 1  wherein said contacting is performed once daily.  
     
     
         15 . A method of treating or preventing a bacterial infection by atypical upper respiratory pathogenic bacteria comprising the step of administering an antibacterially effective amount of a composition comprising a compound selected from the group consisting of: gemifloxacin, ofloxacin, levofloxacin, trovafloxacin, azithromycin, moxifloxacin, ciprofloxacin, clarithromycin, rifampicin and erythromycin; 
 or an antibacterially effective derivative of any of these compounds, to a mammal suspected of having or being at risk of having an infection with atypical upper respiratory pathogenic bacteria.    
     
     
         16 . The method of  claim 15  wherein said bacteria is selected from the group consisting of: a member of the genus Legionella, a member of the genus, Pseudomonas,  Pseudomonas aeruginosa  strain, a  L. pneumophila  strain, a  L. pneumophila  serogroup 1, a  L. pneumophila  serogroup 2, a  L. pneumophila  serogroup 3, a  L. pneumophila  serogroup 4, a  L. pneumophila  serogroup 5, a  L. pneumophila  serogroup 6, a  L. pneumophila  serogroup 7, a  L. pneumophila  serogroup 8, a  L. dumoffii  strain, a  L. longbeacheae  strain, a  L. micdadei  strain, a  L. oakridgensis  strain, a  L. feelei  strain, a  L. anisa  strain, a  L sainthelensi  strain, a  L. bozemanii  strain, a  L. gormanii  strain, a  L. wadsworthii  strain, a  L. jordanis;  strain and a  L. gormanii  strain.